Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 342

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

MGMT Status as a Clinical Biomarker in Glioblastoma

Open access
Butler, Madison, Pongor, Lorinc, Su, Yu-Ting, Xi, Liqiang, Raffeld, Mark, Quezado, Martha, Trepel, Jane, Aldape, Kenneth, Pommier, Yves, Wu, Jing·2020·Trends in Cancer

Abstract

Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have sustained response to treatment. While O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic and promising predictive biomarker in glioblastoma, its value in informing treatment decisions for glioblastoma patients is still debatable. Discrepancies between MGMT promoter methylation status and treatment response in some patients may stem from inconsistencies between MGMT methylation and expression levels in glioblastoma. Here, we discuss MGMT as a biomarker and elucidate the discordance between MGMT methylation, expression, and patient outcome, which currently challenges the implementation of this biomarker in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2020.02.010

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 7

  1. Cao, 2009, The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas, Neurosurgery, 65, 866, 10.1227/01.NEU.0000357325.90347.A1 · doi:10.1227/01.neu.0000357325.90347.a1
  2. Mason, 2012, MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry, J. Cancer Res. Clin. Oncol., 138, 1789, 10.1007/s00432-012-1312-1 · doi:10.1007/s00432-012-1312-1
  3. Wang, 2017, Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas, Pathol. Res. Pract., 213, 1489, 10.1016/j.prp.2017.10.007 · doi:10.1016/j.prp.2017.10.007
  4. Dahlrot, 2018, Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis, Neuropathol. Appl. Neurobiol., 44, 172, 10.1111/nan.12415 · doi:10.1111/nan.12415
  5. Brandes, 2017, Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications, Oncologist, 22, 432, 10.1634/theoncologist.2016-0254 · doi:10.1634/theoncologist.2016-0254
  6. Chen, 2013, MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis, Arch. Med. Res., 44, 281, 10.1016/j.arcmed.2013.04.004 · doi:10.1016/j.arcmed.2013.04.004
  7. Sonoda, 2010, O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma, Int. J. Clin. Oncol., 15, 352, 10.1007/s10147-010-0065-6 · doi:10.1007/s10147-010-0065-6

Cited by

See all 342

Metadata

Authors
Butler, M., Pongor, L., Su, Y.-T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J.
Venue
Trends in Cancer
Publisher
Elsevier BV
Published
2020-05
Volume
6
Issue
5
Pages
380-391
ISSN
  • 2405-8025 (ISSN-L)
  • 2405-8033
OpenAlex
W3012959001
Cited by
342
References
52
FWCI
7.62
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
National Institutes of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MGMT Status as a Clinical Biomarker in Glioblastoma. https://app.cochat.ai/papers/10.1016/j.trecan.2020.02.010
The paper
Butler, M., Pongor, L., Su, Y.-T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J. (2020). MGMT Status as a Clinical Biomarker in Glioblastoma. Trends in Cancer. https://doi.org/10.1016/j.trecan.2020.02.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.